Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on March 5, 2026, reporting events that occurred on March 2, 2026. The filing details the entry into a material definitive agreement involving a new debt financing arrangement with Streeterville Capital, LLC.
Key Financial Metrics and Transaction Details
The Company entered into a Note Purchase Agreement resulting in the following financial obligations and cash flows:
- Total Principal Amount: $20,930,000 (comprising a $10,930,000 A-1 Note and a $10,000,000 B Note).
- Cash Proceeds Received: $10,000,000 paid directly to the Company.
- Restricted Cash: $10,000,000 deposited into a controlled account at Lakeside Bank held by a wholly-owned subsidiary (ALLR Holdings, LLC).
- Interest Rates: 9.00% per annum on the A-1 Note; 5.00% per annum on the B Note.
- Maturity: 18 months from the date of issuance.
- Original Issue Discount (OID): $900,000 on the A-1 Note.
- Transaction Expenses: $30,000 for legal, accounting, and due diligence expenses included in the A-1 Note principal.
Material Changes and Covenants
This transaction represents a significant increase in the Company's debt obligations and introduces specific restrictive covenants:
- Security: Obligations are secured by a Deposit Account Control Agreement (DACA), a guaranty from the subsidiary, and a pledge of all membership interests in the subsidiary.
- Restricted Issuances: The Company is prohibited from issuing new debt or securities with variable conversion prices or anti-dilution provisions without the Lender's prior written consent.
- Redemption Rights: Beginning 6 months after issuance, the Lender may redeem up to $250,000 plus accrued interest per calendar month.
- Trigger Events: The Lender may increase the outstanding balance by 10% (Major Trigger) or 5% (Minor Trigger) upon specific events, up to three times each. Failure to cure a Trigger Event within five trading days results in an automatic Event of Default.
- Default Consequences: Upon default, the balance accelerates immediately, and interest accrues at the lesser of 15% per annum or the maximum rate permitted by law.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary regarding future revenue or operational outlook. However, it highlights significant financial risks:
- Liquidity Constraints: $10,000,000 of the principal is held in a restricted account and is not immediately available for general corporate use.
- Default Risk: The agreement contains aggressive default triggers and penalty interest rates (up to 15%) that could materially impact the Company's financial stability if Trigger Events occur.
- Future Financing Restrictions: The "Restricted Issuance" covenant limits the Company's ability to raise capital through convertible notes or variable-rate equity instruments without Lender approval.
Investor Verification Checklist
- Verify the current cash balance available for operations versus the $10,000,000 restricted in the subsidiary account.
- Review the specific definitions of "Major Trigger Event" and "Minor Trigger Event" in the attached exhibits to assess default probability.
- Confirm the status of the existing Common Stock Purchase Agreement with Tumin Stone Capital LLC (dated January 28, 2026) to ensure it remains compliant with the new covenants.
- Assess the Company's ability to service the monthly redemption payments starting in September 2026.
- Check for any subsequent filings regarding the utilization of the restricted funds or amendments to the Note Purchase Agreement.